You can buy Lucivadadu at the lowest price in the online pharmacy Nextgen.ooo . Vadadustat is an oral hypoxia-inducible factor prolyl-hydroxylase inhibitor used to treat symptomatic anemia associated with chronic kidney disease in adults on chronic maintenance dialysis. One of the most common symptoms of advanced renal disease is anemia, caused primarily by the inability of the kidney to respond to anemic conditions with a corresponding increase in erythropoietin production. The treatment of anemia associated with chronic kidney disease has traditionally involved the administration of exogenous erythropoiesis-stimulating agents, such as darbepoetin alfa, to counter the decrease in endogenous erythropoietin production. While efficacious, the overuse of erythropoietins has been associated with cardiovascular complications, progression of chronic kidney disease, and increases in overall mortality.
 
A relatively new and alternative treatment option for patients with anemia associated with chronic kidney disease is the use of small molecule inhibitors of hypoxia-inducible factor prolyl-hydroxylase (HIF-PH). These agents inhibit prolyl-hydroxylase domain oxygen sensors, mimicking hypoxic conditions and activating hypoxia-inducible factors. These transcription factors serve a multitude of roles, including the stimulation of erythropoiesis.
 
Vadadustat is an orally administered inhibitor of HIF-PH with a safety and efficacy profile non-inferior to darbepoetin alfa for the treatment of anemia in patients with chronic kidney disease undergoing dialysis. It was first approved in Japan in 2020, and in April 2023, it was approved by the EMA for the treatment of symptomatic anemia associated with chronic kidney disease in adults on chronic maintenance dialysis. Vadadustat was approved by the FDA in March 2024.